Search Results

Press Releases

NEURELIS PRESENTS STUDIES ON SEIZURE CLUSTERS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

December 9, 2024

·

11 min read

Press Releases

NEURELIS TO SHARE CLINICAL STUDY DESIGN INSIGHTS FOR INVESTIGATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 AT CHILD NEUROLOGY SOCIETY ANNUAL MEETING

November 12, 2024

·

6 min read

Biotech Beach

NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY

Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.

April 11, 2024

·

8 min read

Biotech Beach

Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024

Neurelis, Inc., today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.

February 26, 2024

·

6 min read

Biotech Beach

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.

December 1, 2023

·

11 min read

Biotech Beach

Neurelis, Inc. to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Neurelis, Inc., a company focused on epilepsy and orphan neurologic disorders, today announced that corporate leadership will participate in and host one-on-one investor meetings at the 6th Annual Evercore ISI HealthCONx Conference, to be held in Miami from November 28-30, 2023.

November 16, 2023

·

1 min read

Biotech Beach

NEURELIS SECURES NEW ORANGE BOOK LISTED U.S. PATENT FOR VALTOCO® (DIAZEPAM NASAL SPRAY) CIV

Neurelis, Inc., a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced that it has secured the issuance of United States Patent No. 11,793,786 (the ‘786 Patent).

November 27, 2023

·

7 min read

Biotech Beach

NEURELIS TO PARTICIPATE IN 11th ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT

Neurelis Inc., is proud to take part in the 11th Annual Sofie’s Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort (EADDL), the largest, worldwide epilepsy community gathering of the year.

October 30, 2023

·

9 min read

Drug Development

NEURELIS TO PRESENT ANALYSES OF VALTOCO® (diazepam nasal spray) CIV AT THE 52nd CHILD NEUROLOGY SOCIETY ANNUAL MEETING

Neurelis, Inc., today announced additional findings from the post hoc analysis of the long-term phase 3 safety study of VALTOCO® (diazepam nasal spray) in a pediatric population, aged 6-17 years, as well as an analysis of real-world data on impact of administration of rescue medication on seizure timing.

October 4, 2023

·

9 min read

Business

Neurelis Announces New Roles for Top Executives to Advance Clinical and Strategic Initiatives and Position for Future Growth

Neurelis, Inc., announced the promotion of Adrian L. Rabinowicz, MD, to Chief Medical Officer and the establishment of a new leadership position of Senior Vice President, Strategic Initiatives for Enrique Carrazana, MD.

May 15, 2023

·

8 min read